1 | Names of Reporting Persons
Frazier Life Sciences Public Fund, L.P. |
2 | Check the appropriate box if a member of a Group (see instructions)
 (a)
 (b)
|
3 | Sec Use Only |
4 | Citizenship or Place of Organization
DELAWARE
|
Number of Shares Beneficially Owned by Each Reporting Person With: | 5 | Sole Voting Power
0.00 | 6 | Shared Voting Power
3,730,419.00 | 7 | Sole Dispositive Power
0.00 | 8 | Shared Dispositive Power
3,730,419.00 |
|
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
3,730,419.00 |
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
 |
11 | Percent of class represented by amount in row (9)
6.8 % |
12 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person: The shares listed in rows 6, 8 and 9 consist of (i) 3,073,467 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. and (ii) 656,952 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P.
The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025 and (iii) 656,952 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.
1 | Names of Reporting Persons
FHMLSP, L.P. |
2 | Check the appropriate box if a member of a Group (see instructions)
 (a)
 (b)
|
3 | Sec Use Only |
4 | Citizenship or Place of Organization
DELAWARE
|
Number of Shares Beneficially Owned by Each Reporting Person With: | 5 | Sole Voting Power
0.00 | 6 | Shared Voting Power
3,730,419.00 | 7 | Sole Dispositive Power
0.00 | 8 | Shared Dispositive Power
3,730,419.00 |
|
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
3,730,419.00 |
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
 |
11 | Percent of class represented by amount in row (9)
6.8 % |
12 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person: The shares listed in rows 6, 8 and 9 consist of (i) 3,073,467 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. and (ii) 656,952 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P.
The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025 and (iii) 656,952 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.
1 | Names of Reporting Persons
FHMLSP, L.L.C. |
2 | Check the appropriate box if a member of a Group (see instructions)
 (a)
 (b)
|
3 | Sec Use Only |
4 | Citizenship or Place of Organization
DELAWARE
|
Number of Shares Beneficially Owned by Each Reporting Person With: | 5 | Sole Voting Power
0.00 | 6 | Shared Voting Power
3,730,419.00 | 7 | Sole Dispositive Power
0.00 | 8 | Shared Dispositive Power
3,730,419.00 |
|
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
3,730,419.00 |
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
 |
11 | Percent of class represented by amount in row (9)
6.8 % |
12 | Type of Reporting Person (See Instructions)
OO |
Comment for Type of Reporting Person: The shares listed in rows 6, 8 and 9 consist of (i) 3,073,467 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. and (ii) 656,952 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P.
The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025 and (iii) 656,952 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.
1 | Names of Reporting Persons
Frazier Life Sciences Public Overage Fund, L.P. |
2 | Check the appropriate box if a member of a Group (see instructions)
 (a)
 (b)
|
3 | Sec Use Only |
4 | Citizenship or Place of Organization
DELAWARE
|
Number of Shares Beneficially Owned by Each Reporting Person With: | 5 | Sole Voting Power
0.00 | 6 | Shared Voting Power
818,607.00 | 7 | Sole Dispositive Power
0.00 | 8 | Shared Dispositive Power
818,607.00 |
|
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
818,607.00 |
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
 |
11 | Percent of class represented by amount in row (9)
1.5 % |
12 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person: The shares listed in rows 6, 8 and 9 consist of (i) 624,804 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P. and (ii) 193,803 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P.
The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025 and (iii) 193,803 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.
1 | Names of Reporting Persons
FHMLSP Overage, L.P. |
2 | Check the appropriate box if a member of a Group (see instructions)
 (a)
 (b)
|
3 | Sec Use Only |
4 | Citizenship or Place of Organization
DELAWARE
|
Number of Shares Beneficially Owned by Each Reporting Person With: | 5 | Sole Voting Power
0.00 | 6 | Shared Voting Power
818,607.00 | 7 | Sole Dispositive Power
0.00 | 8 | Shared Dispositive Power
818,607.00 |
|
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
818,607.00 |
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
 |
11 | Percent of class represented by amount in row (9)
1.5 % |
12 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person: The shares listed in rows 6, 8 and 9 consist of (i) 624,804 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P. and (ii) 193,803 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P.
The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025 and (iii) 193,803 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.
1 | Names of Reporting Persons
FHMLSP Overage, L.L.C. |
2 | Check the appropriate box if a member of a Group (see instructions)
 (a)
 (b)
|
3 | Sec Use Only |
4 | Citizenship or Place of Organization
DELAWARE
|
Number of Shares Beneficially Owned by Each Reporting Person With: | 5 | Sole Voting Power
0.00 | 6 | Shared Voting Power
818,607.00 | 7 | Sole Dispositive Power
0.00 | 8 | Shared Dispositive Power
818,607.00 |
|
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
818,607.00 |
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
 |
11 | Percent of class represented by amount in row (9)
1.5 % |
12 | Type of Reporting Person (See Instructions)
OO |
Comment for Type of Reporting Person: The shares listed in rows 6, 8 and 9 consist of (i) 624,804 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P. and (ii) 193,803 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P.
The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025 and (iii) 193,803 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.
1 | Names of Reporting Persons
Frazier Life Sciences X, L.P. |
2 | Check the appropriate box if a member of a Group (see instructions)
 (a)
 (b)
|
3 | Sec Use Only |
4 | Citizenship or Place of Organization
DELAWARE
|
Number of Shares Beneficially Owned by Each Reporting Person With: | 5 | Sole Voting Power
0.00 | 6 | Shared Voting Power
114,541.00 | 7 | Sole Dispositive Power
0.00 | 8 | Shared Dispositive Power
114,541.00 |
|
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
114,541.00 |
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
 |
11 | Percent of class represented by amount in row (9)
0.2 % |
12 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person: The shares listed in rows 6, 8 and 9 consist of (i) 87,424 shares of Common Stock held directly by Frazier Life Sciences X, L.P. and (ii) 27,117 shares of Common Stock issuable to Frazier Life Sciences X, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P.
The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025 and (iii) 27,117 shares of Common Stock issuable to Frazier Life Sciences X, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.
1 | Names of Reporting Persons
FHMLS X, L.P. |
2 | Check the appropriate box if a member of a Group (see instructions)
 (a)
 (b)
|
3 | Sec Use Only |
4 | Citizenship or Place of Organization
DELAWARE
|
Number of Shares Beneficially Owned by Each Reporting Person With: | 5 | Sole Voting Power
0.00 | 6 | Shared Voting Power
114,541.00 | 7 | Sole Dispositive Power
0.00 | 8 | Shared Dispositive Power
114,541.00 |
|
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
114,541.00 |
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
 |
11 | Percent of class represented by amount in row (9)
0.2 % |
12 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person: The shares listed in rows 6, 8 and 9 consist of (i) 87,424 shares of Common Stock held directly by Frazier Life Sciences X, L.P. and (ii) 27,117 shares of Common Stock issuable to Frazier Life Sciences X, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P.
The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025 and (iii) 27,117 shares of Common Stock issuable to Frazier Life Sciences X, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.
1 | Names of Reporting Persons
FHMLS X, L.L.C. |
2 | Check the appropriate box if a member of a Group (see instructions)
 (a)
 (b)
|
3 | Sec Use Only |
4 | Citizenship or Place of Organization
DELAWARE
|
Number of Shares Beneficially Owned by Each Reporting Person With: | 5 | Sole Voting Power
0.00 | 6 | Shared Voting Power
114,541.00 | 7 | Sole Dispositive Power
0.00 | 8 | Shared Dispositive Power
114,541.00 |
|
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
114,541.00 |
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
 |
11 | Percent of class represented by amount in row (9)
0.2 % |
12 | Type of Reporting Person (See Instructions)
OO |
Comment for Type of Reporting Person: The shares listed in rows 6, 8 and 9 consist of (i) 87,424 shares of Common Stock held directly by Frazier Life Sciences X, L.P. and (ii) 27,117 shares of Common Stock issuable to Frazier Life Sciences X, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P.
The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025 and (iii) 27,117 shares of Common Stock issuable to Frazier Life Sciences X, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.
1 | Names of Reporting Persons
Frazier Life Sciences XI, L.P. |
2 | Check the appropriate box if a member of a Group (see instructions)
 (a)
 (b)
|
3 | Sec Use Only |
4 | Citizenship or Place of Organization
DELAWARE
|
Number of Shares Beneficially Owned by Each Reporting Person With: | 5 | Sole Voting Power
0.00 | 6 | Shared Voting Power
304,989.00 | 7 | Sole Dispositive Power
0.00 | 8 | Shared Dispositive Power
304,989.00 |
|
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
304,989.00 |
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
 |
11 | Percent of class represented by amount in row (9)
0.6 % |
12 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person: The shares listed in rows 6, 8 and 9 consist of (i) 232,784 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. and (ii) 72,205 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 16, 2025. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P.
The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025 and (iii) 72,205 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.
1 | Names of Reporting Persons
FHMLS XI, L.P. |
2 | Check the appropriate box if a member of a Group (see instructions)
 (a)
 (b)
|
3 | Sec Use Only |
4 | Citizenship or Place of Organization
DELAWARE
|
Number of Shares Beneficially Owned by Each Reporting Person With: | 5 | Sole Voting Power
0.00 | 6 | Shared Voting Power
304,989.00 | 7 | Sole Dispositive Power
0.00 | 8 | Shared Dispositive Power
304,989.00 |
|
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
304,989.00 |
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
 |
11 | Percent of class represented by amount in row (9)
0.6 % |
12 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person: The shares listed in rows 6, 8 and 9 consist of (i) 232,784 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. and (ii) 72,205 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 16, 2025. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P.
The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025 and (iii) 72,205 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.
1 | Names of Reporting Persons
FHMLS XI, L.L.C. |
2 | Check the appropriate box if a member of a Group (see instructions)
 (a)
 (b)
|
3 | Sec Use Only |
4 | Citizenship or Place of Organization
DELAWARE
|
Number of Shares Beneficially Owned by Each Reporting Person With: | 5 | Sole Voting Power
0.00 | 6 | Shared Voting Power
304,989.00 | 7 | Sole Dispositive Power
0.00 | 8 | Shared Dispositive Power
304,989.00 |
|
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
304,989.00 |
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
 |
11 | Percent of class represented by amount in row (9)
0.6 % |
12 | Type of Reporting Person (See Instructions)
OO |
Comment for Type of Reporting Person: The shares listed in rows 6, 8 and 9 consist of (i) 232,784 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. and (ii) 72,205 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 16, 2025. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P.
The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025 and (iii) 72,205 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.
1 | Names of Reporting Persons
Frazier Life Sciences XII, L.P. |
2 | Check the appropriate box if a member of a Group (see instructions)
 (a)
 (b)
|
3 | Sec Use Only |
4 | Citizenship or Place of Organization
DELAWARE
|
Number of Shares Beneficially Owned by Each Reporting Person With: | 5 | Sole Voting Power
0.00 | 6 | Shared Voting Power
532,256.00 | 7 | Sole Dispositive Power
0.00 | 8 | Shared Dispositive Power
532,256.00 |
|
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
532,256.00 |
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
 |
11 | Percent of class represented by amount in row (9)
1.0 % |
12 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person: The shares listed in rows 6, 8 and 9 consist of (i) 406,246 shares of Common Stock held directly by Frazier Life Sciences XII, L.P. and (ii) 126,010 shares of Common Stock issuable to Frazier Life Sciences XII, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025. FHMLS XII, L.P. is the general partner of Frazier Life Sciences XII, L.P. and FHMLS XII, L.L.C. is the general partner of FHMLS XII, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XII, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XII, L.P.
The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025 and (iii) 126,010 shares of Common Stock issuable to Frazier Life Sciences XII, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.
1 | Names of Reporting Persons
FHMLS XII, L.P. |
2 | Check the appropriate box if a member of a Group (see instructions)
 (a)
 (b)
|
3 | Sec Use Only |
4 | Citizenship or Place of Organization
DELAWARE
|
Number of Shares Beneficially Owned by Each Reporting Person With: | 5 | Sole Voting Power
0.00 | 6 | Shared Voting Power
532,256.00 | 7 | Sole Dispositive Power
0.00 | 8 | Shared Dispositive Power
532,256.00 |
|
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
532,256.00 |
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
 |
11 | Percent of class represented by amount in row (9)
1.0 % |
12 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person: The shares listed in rows 6, 8 and 9 consist of (i) 406,246 shares of Common Stock held directly by Frazier Life Sciences XII, L.P. and (ii) 126,010 shares of Common Stock issuable to Frazier Life Sciences XII, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025. FHMLS XII, L.P. is the general partner of Frazier Life Sciences XII, L.P. and FHMLS XII, L.L.C. is the general partner of FHMLS XII, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XII, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XII, L.P.
The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025 and (iii) 126,010 shares of Common Stock issuable to Frazier Life Sciences XII, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.
1 | Names of Reporting Persons
FHMLS XII, L.L.C. |
2 | Check the appropriate box if a member of a Group (see instructions)
 (a)
 (b)
|
3 | Sec Use Only |
4 | Citizenship or Place of Organization
DELAWARE
|
Number of Shares Beneficially Owned by Each Reporting Person With: | 5 | Sole Voting Power
0.00 | 6 | Shared Voting Power
532,256.00 | 7 | Sole Dispositive Power
0.00 | 8 | Shared Dispositive Power
532,256.00 |
|
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
532,256.00 |
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
 |
11 | Percent of class represented by amount in row (9)
1.0 % |
12 | Type of Reporting Person (See Instructions)
OO |
Comment for Type of Reporting Person: The shares listed in rows 6, 8 and 9 consist of (i) 406,246 shares of Common Stock held directly by Frazier Life Sciences XII, L.P. and (ii) 126,010 shares of Common Stock issuable to Frazier Life Sciences XII, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025. FHMLS XII, L.P. is the general partner of Frazier Life Sciences XII, L.P. and FHMLS XII, L.L.C. is the general partner of FHMLS XII, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XII, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XII, L.P.
The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025 and (iii) 126,010 shares of Common Stock issuable to Frazier Life Sciences XII, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.
1 | Names of Reporting Persons
James N. Topper |
2 | Check the appropriate box if a member of a Group (see instructions)
 (a)
 (b)
|
3 | Sec Use Only |
4 | Citizenship or Place of Organization
UNITED STATES
|
Number of Shares Beneficially Owned by Each Reporting Person With: | 5 | Sole Voting Power
0.00 | 6 | Shared Voting Power
5,500,812.00 | 7 | Sole Dispositive Power
0.00 | 8 | Shared Dispositive Power
5,500,812.00 |
|
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
5,500,812.00 |
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
 |
11 | Percent of class represented by amount in row (9)
9.9 % |
12 | Type of Reporting Person (See Instructions)
IN |
Comment for Type of Reporting Person: The shares listed in rows 6, 8 and 9 consist of (i) 3,073,467 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P., (ii) 656,952 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, (iii) 624,804 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P., (iv) 193,803 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, (v) 87,424 shares of Common Stock held directly by Frazier Life Sciences X, L.P., (vi) 27,117 shares of Common Stock issuable to Frazier Life Sciences X, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, (vii) 232,784 shares of Common Stock held directly by Frazier Life Sciences XI, L.P., (viii) 72,205 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, (ix) 406,246 shares of Common Stock held directly by Frazier Life Sciences XII, L.P. and (x) 126,010 shares of Common Stock issuable to Frazier Life Sciences XII, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.
FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P. FHMLS XII, L.P. is the general partner of Frazier Life Sciences XII, L.P. and FHMLS XII, L.L.C. is the general partner of FHMLS XII, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XII, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XII, L.P.
The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025, (iii) 656,952 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, (iv) 193,803 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, (v) 27,117 shares of Common Stock issuable to Frazier Life Sciences X, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, (vi) 72,205 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, and (vii) 126,010 shares of Common Stock issuable to Frazier Life Sciences XII, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.
1 | Names of Reporting Persons
Patrick J. Heron |
2 | Check the appropriate box if a member of a Group (see instructions)
 (a)
 (b)
|
3 | Sec Use Only |
4 | Citizenship or Place of Organization
UNITED STATES
|
Number of Shares Beneficially Owned by Each Reporting Person With: | 5 | Sole Voting Power
0.00 | 6 | Shared Voting Power
5,500,812.00 | 7 | Sole Dispositive Power
0.00 | 8 | Shared Dispositive Power
5,500,812.00 |
|
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
5,500,812.00 |
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
 |
11 | Percent of class represented by amount in row (9)
9.9 % |
12 | Type of Reporting Person (See Instructions)
IN |
Comment for Type of Reporting Person: The shares listed in rows 6, 8 and 9 consist of (i) 3,073,467 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P., (ii) 656,952 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, (iii) 624,804 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P., (iv) 193,803 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, (v) 87,424 shares of Common Stock held directly by Frazier Life Sciences X, L.P., (vi) 27,117 shares of Common Stock issuable to Frazier Life Sciences X, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, (vii) 232,784 shares of Common Stock held directly by Frazier Life Sciences XI, L.P., (viii) 72,205 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, (ix) 406,246 shares of Common Stock held directly by Frazier Life Sciences XII, L.P. and (x) 126,010 shares of Common Stock issuable to Frazier Life Sciences XII, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.
FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P. FHMLS XII, L.P. is the general partner of Frazier Life Sciences XII, L.P. and FHMLS XII, L.L.C. is the general partner of FHMLS XII, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XII, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XII, L.P.
The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025, (iii) 656,952 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, (iv) 193,803 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, (v) 27,117 shares of Common Stock issuable to Frazier Life Sciences X, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, (vi) 72,205 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, and (vii) 126,010 shares of Common Stock issuable to Frazier Life Sciences XII, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.
1 | Names of Reporting Persons
Albert Cha |
2 | Check the appropriate box if a member of a Group (see instructions)
 (a)
 (b)
|
3 | Sec Use Only |
4 | Citizenship or Place of Organization
UNITED STATES
|
Number of Shares Beneficially Owned by Each Reporting Person With: | 5 | Sole Voting Power
0.00 | 6 | Shared Voting Power
4,549,026.00 | 7 | Sole Dispositive Power
0.00 | 8 | Shared Dispositive Power
4,549,026.00 |
|
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
4,549,026.00 |
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
 |
11 | Percent of class represented by amount in row (9)
8.3 % |
12 | Type of Reporting Person (See Instructions)
IN |
Comment for Type of Reporting Person: The shares listed in rows 6, 8 and 9 consist of (i) 3,073,467 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P., (ii) 656,952 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, (iii) 624,804 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P., and (iv) 193,803 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.
FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P.
The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025, (iii) 656,952 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, and (iv) 193,803 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.
1 | Names of Reporting Persons
James Brush |
2 | Check the appropriate box if a member of a Group (see instructions)
 (a)
 (b)
|
3 | Sec Use Only |
4 | Citizenship or Place of Organization
UNITED STATES
|
Number of Shares Beneficially Owned by Each Reporting Person With: | 5 | Sole Voting Power
0.00 | 6 | Shared Voting Power
4,549,026.00 | 7 | Sole Dispositive Power
0.00 | 8 | Shared Dispositive Power
4,549,026.00 |
|
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
4,549,026.00 |
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
 |
11 | Percent of class represented by amount in row (9)
8.3 % |
12 | Type of Reporting Person (See Instructions)
IN |
Comment for Type of Reporting Person: The shares listed in rows 6, 8 and 9 consist of (i) 3,073,467 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P., (ii) 656,952 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, (iii) 624,804 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P., and (iv) 193,803 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.
FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P.
The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025, (iii) 656,952 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, and (iv) 193,803 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.
1 | Names of Reporting Persons
Daniel Estes |
2 | Check the appropriate box if a member of a Group (see instructions)
 (a)
 (b)
|
3 | Sec Use Only |
4 | Citizenship or Place of Organization
UNITED STATES
|
Number of Shares Beneficially Owned by Each Reporting Person With: | 5 | Sole Voting Power
0.00 | 6 | Shared Voting Power
837,245.00 | 7 | Sole Dispositive Power
0.00 | 8 | Shared Dispositive Power
837,245.00 |
|
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
837,245.00 |
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
 |
11 | Percent of class represented by amount in row (9)
1.5 % |
12 | Type of Reporting Person (See Instructions)
IN |
Comment for Type of Reporting Person: The shares listed in rows 6, 8 and 9 consist of (i) 232,784 shares of Common Stock held directly by Frazier Life Sciences XI, L.P., (ii) 72,205 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, (iii) 406,246 shares of Common Stock held directly by Frazier Life Sciences XII, L.P. and (iv) 126,010 shares of Common Stock issuable to Frazier Life Sciences XII, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.
FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P. FHMLS XII, L.P. is the general partner of Frazier Life Sciences XII, L.P. and FHMLS XII, L.L.C. is the general partner of FHMLS XII, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XII, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XII, L.P.
The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025, (iii) 72,205 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, and (iv) 126,010 shares of Common Stock issuable to Frazier Life Sciences XII, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.